Short-Term Resveratrol Exposure Causes *In Vitro* and *In Vivo* Growth Inhibition and Apoptosis of Bladder Cancer Cells

Mo-Li Wu, Hong Li, Li-Jun Yu, Xiao-Yan Chen, Qing-You Kong, Xue Song, Xiao-Hong Shu, Jia Liu*

Liaoning Laboratory of Cancer Genetics and Epigenomics and Department of Cell Biology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China

**Abstract**

Conventional adjuvant chemotherapies for bladder transitional cell carcinomas (TCCs) may cause strong systemic toxicity and local irritation. Non-toxic resveratrol inhibits TCC cell growth but its feasibility in clinical management of TCCs remains obscure. This study aimed to evaluate the safety and anti-TCC efficacy of resveratrol, using the experimental models closer to the clinical treatment condition. Human TCC EJ cells were exposed to 100 μM, 150 μM and 200 μM resveratrol respectively for 1 hour and 2 hours to mimic intravesical drug instillation and the cell responses were analyzed by multiple experimental approaches. An orthotopic TCC nude mouse model was established by injecting EJ cells into the sub-urothelial layer and used for short-term intravesical resveratrol instillation. The safety of resveratrol instillation was evaluated and compared with that of MCC. The results revealed that 2 h 150 μM or 200 μM resveratrol treatment led to remarkable S phase arrest and apoptosis at 72 h time-point, accompanied with attenuated phosphorylation, nuclear translocation and transcription of STAT3, down-regulation of STAT3 downstream genes (survivin, cyclinD1, c-Myc and VEGF) and nuclear translocations of Sirt1 and p53. The importance of STAT3 signaling in cell growth was confirmed by treating EJ cells with JAK2 inhibitor tyrphostin AG490. The efficacy and safety of resveratrol instillation were proved by the findings from nude mouse orthotopic xenograft models, because this treatment caused growth suppression, distinctive apoptosis and STAT3 inactivation of the transplanted tumors without affecting normal urothelium. Our results thus suggest for the first time the practical values of resveratrol as a safe and effective agent in the post-operative treatment of TCCs.

**Introduction**

Bladder cancer is the commonest malignancy of the urinary tract, of which 90% is transitional cell carcinoma (TCC). Transurethral resection followed by intravesical chemotherapy is the standard care of TCC patients [1]. Recurrence is the leading risk of TCC patients because of the difficulty to radically remove the aggressive tumors [2]. Consequently, adjuvant intravesical chemotherapies become the major approaches to prevent TCC relapse. Bacillus Calmette-Guerin, interferon-α, cisplatin, mitomycin C (MMC) and their combinations are conventionally used in clinical practice, while their efficacies are variable [3,4] and usually cause strong systemic toxicity and local complications such as hemorrhagic cystitis [2]. It is therefore in urgent need to explore lesser toxic and more effective approach for better management of TCCs.

Resveratrol has been regarded as a non-toxic polyphenolic compound that found in grapes, berries, peanuts and red wine [5]. A body of evidence shows that resveratrol is able to inhibit the growth of many cancers such as leukemia, breast cancer and primary brain tumors [6–8]. In the case of bladder cancers, resveratrol effectively decreases cell viability and induces apoptosis of human and murine bladder cancer cells [9–12]. Nevertheless, the practical value of resveratrol in anti-TCC therapy has not been addressed by the use of more clinically relevant experimental model(s) and in the way of local drug administration. In the current study, human TCC cell line, EJ [13], was treated in short term by resveratrol to mimic clinical drug instillation [14]. The cellular and molecular responses of EJ cells to the treatment were analyzed by multiple approaches. Meanwhile, an orthotopic TCC nude mouse model was established by injecting EJ cells into the sub-urothelial layer and treated by resveratrol in the manner similar with intravesical drug instillation [15]. The cellular and molecular responses to those treatments were evaluated thereafter.

**Materials and Methods**

**Cell Culture and Treatments**

Human TCC EJ cells [13] were cultured in Dulbecco’s modified Eagle’s essential medium (DMEM) containing 10% fetal bovine serum (Gibco Life Science, Grand Island, NY, USA) under 57°C and 5% CO₂ conditions. The cells (5×10⁴/ml) were plated to culture dishes (NUNC, Denmark) and incubated for 24 h before the experiments.

Resveratrol (Res; Sigma Chemical, Inc, St. Louis, MO) was dissolved in dimethylsulfoxide (DMSO; Sigma) and diluted with...
Figure 1. Short-term resveratrol treatments reduced cell viability and the growth of EJ bladder cancer cells, and caused apoptosis of EJ cells in vitro. A. Schematic diagram of short-term in vitro resveratrol treatment. B. MTT assay performed at 72 h after the treatments showed that short-term resveratrol exposure decreased cell viability and suppressed EJ cell growth in dose- and time-dependent manner. *, compared with N group, \(P<0.01\); **, compared among 100 \(\mu\)M, 150 \(\mu\)M and 200 \(\mu\)M Res-treated groups at 1.5 h and 2.0 h, \(P<0.01\); #, compared with 1 h 150 \(\mu\)M Res treatment, \(P>0.05\); $, compared with 1 h 200 \(\mu\)M Res treatment, \(P>0.05\); ##, compared with 1 h 100 \(\mu\)M Res treatment, \(P<0.05\). \& compared among 1.0 h, 1.5 h or 2.0 h 100 \(\mu\)M Res-treated groups, \(P<0.01\); \&, compared among 1.0 h, 1.5 h or 2.0 h 150 \(\mu\)M Res-treated groups, \(P<0.01\); ', compared among 1.0 h, 1.5 h or 2.0 h 200 \(\mu\)M Res-treated groups, \(P<0.01\). C. H&E staining and TUNEL assay (inset of the cycled region) performed on 2 h 200 \(\mu\)M resveratrol treated-EJ cells at 72 h. D. Flow cytometry was performed to determine cell cycle distribution and apoptosis in EJ cells after short-term resveratrol treatments. 150 \(\mu\)M and 200 \(\mu\)M resveratrol treatments for 2 h could both arrest cell cycle at S phase and increase apoptotic fractions at 72 h in dose-dependent fashion.

doi:10.1371/journal.pone.0089806.g001
culture medium to the working concentrations just before use. The cells under normal culture condition, treated by 0.2% DMSO and exposed to 100 μM Res for 48 h were used as normal, background and efficacy controls, respectively. As shown in the diagram (Figure 1A), EJ cells were treated by 100 μM, 150 μM or 200 μM Res for 1 h, 1.5 h or 2 h in 24 h intervals. After 1 h and 2 h treatments, Res containing media were replaced with normal medium upon 3 washes. Therefore, EJ cells were exposed to different concentrations of Res for 3 times (once a day) during the 72 h experiment (Figure 1A). Cell numbers and viabilities were checked in 12 h intervals. The cell-bearing coverslips were fixed in cold acetone or 4% paraformaldehyde (pH 7.4) for morphological and immunocytochemical examinations. The experimental groups were set in triplicate and the experiments were repeated for three times to establish confidential conclusion.

Cell Proliferation and Death Assays
The effects of resveratrol on cell proliferation were determined by 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assay described elsewhere [8]. The results were shown as percentage of cell viability (OD of the experiment samples/OD of the control) or OD values. Terminal deoxynucleotide transferase (TdT)-mediated dUTP-biotin nick-end labeling (TUNEL) assay was employed to detect apoptotic cells according to producer’s instructions (Promega Corporation, USA). Haematoxylin and eosin (H/E) staining was performed to observe the morphological changes of EJ cells after treatment.

Flow Cytometry
The harvested cells of the experimental groups were fixed in ethanol for staining with DNA dye and resuspended in 0.5 ml to 1 ml propidium iodide (PI) solution containing RNase and Table 1. Sequences of RT-PCR Primers.

| Parameters | Primer Sequences | Annealing Temperature (°C) | Product Size (bp) | Reference |
|------------|------------------|-----------------------------|------------------|-----------|
| STAT3 F: 5'-gggtggagaagacactagcgttac-3' | 58 | 198 | [16] |
| R: 5'-ggcgcctacttctgctagc-3' | 58 | 439 | [17] |
| survivin F: 5'-ggcatgggacctcagctgtc-3' | 58 | 265 | [18] |
| R: 5'-cagaggtcctacttcatgccga-3' | 57 | 257 | [19] |
| c-Myc F: 5'-tgttttctaccccttcaccttc-3' | 56 | 257 | [19] |
| R: 5'-gatcgcgtctgcagctttgccg-3' | 57 | 257 | [19] |
| cyclin D1 F: 5'-ctgtgtcggagctgggaacatat-3' | 58 | 198 | [16] |
| R: 5'-ttctatggccacrgggaagaccc-3' | 58 | 439 | [17] |

Figure 2. Evaluation of the levels of STAT3, p-STAT3, cyclinD1, survivin, c-Myc and VEGF in normally cultured EJ cells and the cells treated by resveratrol shortly (200 μM for 2 h) or constantly (100 μM for 48 h) by RT-PCR (A), immunocytochemical staining (B) and Western blotting (C).

doi:10.1371/journal.pone.0089806.g002
incubated at 37°C for 30 minutes. Cell-cycle profiles and the fractionations of apoptotic cells were obtained with a FACSVantage flow cytometer (Becton Dickinson, San Jose, CA, USA) and data were analyzed with ModFit software (Verity Software House, USA).

RNA Isolation and Reverse Transcription–Polymerase Chain Reaction

Total cellular RNA was isolated using Trizol solution (Life Technologies, Grand Island, NY). By the method described elsewhere [8], reverse transcription (RT) was performed on RNA samples, followed by polymerase chain reaction (PCR) with the primers (Table 1) for STAT3, c-Myc, cyclin-D1 and survivin [16–19]. The PCR products were resolved on 1% agarose gel containing ethidium bromide (0.5 µg/ml), visualized and photographed using UVP Biospectrum Imaging System (UVP, Inc, Upland, CA). The β-actin PCR products generated from the same RT solution were cited as quantitative controls.

Immunocytochemical and Immunofluorescence Staining

Immunocytochemical staining (ICC) was performed on the coverslips obtained from each of the experimental groups by the method described elsewhere [20]. The antibodies against human STAT3, p-STAT3, survivin, cyclin-D1, c-Myc, VEGF, Sirt1 and p53 were purchased from Santa Cruz Biotechnology, Inc, CA. Color reaction was developed using 3, 3′-diaminobenzidine tetrahydrochloride (DAB). According to the labeling intensity, the staining results were evaluated by two independent researchers and scored as negative (−) if no immunolabeling was observed in target cells, weakly positive (+) if the labeling was faint, moderately positive (++), and strongly positive (+++++) when the labeling was stronger or distinctly stronger than (+++). For immunofluorescence staining (IF), the cell bearing coverslips were rinsed with phosphate-buffered solution (PBS; pH 7.4) for 3 times, blocked with 10% goat serum in PBS (pH 7.4) for 20 minutes, incubated overnight with primary antibody against target protein and finally co-incubated with fluorescence-labeled goat anti-rabbit or rabbit anti-mouse IgG (1:200; Santa Cruz Biotechnology, Inc) at 37°C for 60 minutes in darkness. The nuclei were labeled by DAPI (blue fluorescence). The coverslips were observed and photographed under a fluorescence microscope (BX53F, Olympus, Japan).

Protein Preparation and Western Blotting

Total cellular proteins were prepared from the cells under different culture conditions [20]. The sample proteins (50 µg/well) were separated in 10% sodium dodecylsulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane (Amersham, Buckinghamshire, UK). The membrane was blocked with 5% skimmed milk in TBS-T (10 mM Tris-HCl, pH 8.0, 150 mM NaCl and 0.5% Tween 20) at 4°C, rinsed 10 minutes for three times with TBS-T, followed by 3 h incubation at room temperature with the first antibody and then 1 h incubation with HRP-conjugated anti-mouse or anti-rabbit IgG (Zymed Lab, Inc). The bound antibody was detected using the enhanced chemiluminescence system (Roche GmbH, Mannheim, Germany). After removing the labeling signal by incubation with stripping buffer [8], the membrane was reprobed with other antibodies one by one until all of the parameters were examined.

### Table 2. Statues of STAT3, p-STAT3 and STAT3 downstream genes in EJ cells and EJ transplanted tumors under different experimental conditions.

|                        | EJ cells | Transplanted tumors |
|------------------------|----------|---------------------|
|                        | N        | 200 µM Res* | AG490 (µM) | NaCl* | 200 µM Res* |
|                        | 50 µM    | 80 µM |
| STAT3                  | +++      | +          | ++        | +     | +++        | ++        |
| p-STAT3                | ++       | −          | −         | −     | ++         | −         |
| cyclinD1               | ++       | +          | −         | −     | +++        | ++        |
| Survivin               | ++       | +          | +         | −     | +++        | +         |
| c-Myc                  | ++       | +          | +         | −     | +++        | +         |
| VEGF                   | +++      | +          | +         | −     | +++        | +         |

*EJ cells treated by 2 h 200 µM Res in one day intervals for 3 times and the transplanted tumors treated by 2 h 200 µM Res or 0.9% NaCl in two-day intervals for 13 times.

#Densities of nuclear immuno-labeling.
doi:10.1371/journal.pone.0089806.t002

Figure 3. Immunocytochemical evaluation of the expression and intracellular distribution of STAT3, p-STAT3, cyclinD1, survivin, c-Myc and VEGF in EJ cells without and with AG490 treatments.
doi:10.1371/journal.pone.0089806.g003
Inhibition of STAT3 Activation with AG490

JAK2-specific inhibitor AG490 (Sigma) [21] was dissolved in DMSO and diluted to the final concentrations of 50 μM and 80 μM with culture medium. Four experimental groups were set as follows: Group 1, normal culture; Group 2, treatment with 1.2% DMSO as background control; Groups 3 and 4, treatment with 50 μM or 80 μM AG490. The effects of AG490 on cell proliferation were determined by MTT, flow cytometry and coverslip-based morphological and ICC staining for STAT3, p-STAT3, cyclinD1, survivin, c-Myc and VEGF. RNA and protein samples were prepared from all groups for RT-PCR and Western blot analyses.

Ethics Statement

Prior to the animal experiments, the research protocols were reviewed and approved by Animal Care and Use Committee of Dalian Medical University. All work involving experimental animals was performed in full compliance with NIH (National Institutes of Health) Guidelines for the Care and Use of Laboratory Animals. All experiments were performed under chloral hydrate anesthesia and all efforts were made to minimize suffering.

Orthotopic TCC Model and Intravesical Treatment

Female BALB/c-nude mice (4 weeks, 14–16 g body weight) were raised under specific pathogen free (SPF) conditions. For establishing orthotopic bladder cancer model [22], mice were anesthetized intraperitoneally with 3.3% chloral hydrate (0.1 ml/10 g mice body weight) [23]. The state of anaesthesia was evaluated by loss of righting reflex (LORR), and time to induce LORR was usually between 5–10 minutes. In the germfree isolator, the mice urinary bladders were exposed through a low midline incision; 20 μl EJ cell suspension (1 × 10^6 cells) was injected into its sub-epithelial layer and the appearance of “semitransparent bubbles” indicated successful inoculation. Three days later, the mice were randomly divided into two groups (10 mice/group) and treated by 50 μl 200 μM resveratrol or 50 μl 0.9% NaCl in two-day intervals. After urine evacuation, a 24-gauge Teflon-coated catheter was introduced into the lumen of the bladder. To avoid liquid leaking, the catheter attached with syringe was held in place for 40 minutes. All of the mice were anesthetized safely and usually recovered from anesthesia after 2 hours. By the end of 28 day experiment, the whole bladders were harvested, weighed and then subjected to histological and immunohistochemical (IHC) examinations. Apoptosis was detected by the TUNEL assay and its indexes were obtained by counting TUNEL-positive cells versus over 1000 observed cells in the tumor sections [24].

Evaluation of Local Irritation and Systemic Toxicity

5-week old ICR female mice (5 mice/group) were intravesically treated with 50 μl of 200 μM resveratrol. The treatment was performed for 6 times in 2-day intervals. The mice treated with 50 μl of 2 mg/ml MMC (Sigma-Aldrich, dissolved in 0.9% NaCl) [25] in the same administration manner were cited as control. By the end of the treatments, the body weights were counted and the response(s) of bladder tissues to the treatments were examined in terms of mucosal integrity, capillary congestion and hemorrhage.
The differences in continuous variables were assessed by Student t test or one-way ANOVA. Statistical significance was defined as *P* < 0.05.

**Results**

**Short-term Resveratrol Treatment Suppressed TCC Cell Growth**

MTT assay revealed that EJ cell growth was suppressed by short-term resveratrol treatments in dose- and time-related fashions (Figure 1B). H/E staining and TUNEL assay showed frequent apoptotic death in 2 h 150 μM and 200 μM Res-treated groups (Figure 1C). Flow cytometry showed that 2 h 150 μM and 200 μM Res treatments caused S-phase arrest and apoptosis in EJ cell populations. As shown in Figure 1D, the G1 and S fractions of EJ cells were 62.6% and 33% in normally cultured cells, which changed to 23.9% and 76.1% in 2 h 150 μM Res treated and 17.7% and 82.3% in 2 h 200 μM Res treated populations, respectively. The percentages of apoptosis in normally cultured, 2 h 150 μM Res- and 200 μM Res-treated groups were 0.394%, 4.98% and 11.4% at 72 h time point (Figure 1D). The growth of EJ cells was effectively inhibited by the constant treatment of 100 μM resveratrol.
Resveratrol Inhibited STAT3 Transcription and Activation

Because of the critical roles of activated STAT3 signaling in bladder TCC cells [26], the effect of resveratrol on STAT3 signaling in EJ cells was analyzed by RT-PCR using the RNA samples extracted from the EJ cells without and with Res treatment. As shown in Figure 2A, STAT3 was expressed in normally cultured EJ cells and down-regulated after 2 h 200 μM Res treatment for 72 hours. ICC staining performed on the same experimental groups revealed strong STAT3 staining (+++) in either cytosolic space or nuclei of normally cultured EJ cells, which apparently weakened (+) after 72 hours of 2 h 200 μM Res treatment (Figure 2B; Table 2). It was also found that p-STAT3 was mainly localized in the nuclei of EJ cells and was diminished after 2 h 200 μM Res treatment for 72 hours (Figure 2B; Table 2). In accordance with the results of RT-PCR and ICC, Western blotting showed that 2 h 200 μM Res treatment caused distinct STAT3 and p-STAT3 reduction (Figure 2C). To further elucidate the effects of 2 h Res treatment on STAT3 signaling, the levels of STAT3 downstream genes (c-Myc, survivin, cyclinD1 and VEGF) in normally cultured and 2 h 200 μM Res treated EJ cells were examined by the methods described above. As shown in Figure 2, the expression of c-Myc, survivin, cyclinD1 and VEGF was suppressed in 2 h 200 μM Res-treated EJ cells (Table 2). Similar findings could also be detected in EJ cells treated constantly by 100 μM resveratrol for 48 h.

Inhibitory Effects of AG490 on EJ Cells

To determine the significance of resveratrol-caused STAT3 inhibition, AG490, a selective inhibitor of STAT3 phosphorylation, was used to treat EJ cells [21]. Immunocytochemical staining demonstrated that STAT3 phosphorylation was inhibited in AG490-treated cells in terms of reduction of STAT3 and p-STAT3 nuclear labeling (Figure 3; Table 2). The proliferation of EJ cells was suppressed by AG490 in dose- and time-related fashion (Figure 4A). Flow cytometry analysis demonstrated that 48 hour 50 μM and 80 μM AG490 treatments caused S-phase arrest without inducing distinct apoptosis. The G1 and S fractions were 62.6% and 33% in normally cultured, 50.4% and 49.6% in 50 μM AG490 treated and 17.9% and 75.7% in 80 μM AG490 treated EJ cells (Figure 4B). These results are in consistence with those of short-term resveratrol treatments. The percentages of apoptosis in normally cultured, 50 μM AG490- and 80 μM AG490-treated groups at 48 h time point were 0.394%, 0.194% and 1.77%, respectively (Figure 4B). In comparison with normally cultured EJ cells, c-Myc, cyclinD1, survivin and VEGF expressions were down-regulated in AG490-treated cells (Figure 3, Figure 4C and D; Table 2).

Intravesical Resveratrol Treatment Inhibited Orthotopic Tumor Growth

H/E staining was performed on the inoculated sites and confirmed that the successful rate of orthotopic tumor implantation was 100% (20/20). The schematic diagram of intravesical resveratrol treatment and dosing schedule was shown in Figure 5A. The tumor burdens were determined by weighing the whole bladders harvested from all groups [27], which revealed the greater mean bladder weight in NaCl-treated control group than that in resveratrol-treated group (0.03362 g vs 0.01625 g, P<0.01; Figure 5B and C). TUNEL assay performed on orthotopic tumor samples with and without short-term resveratrol instillation demonstrated remarkable apoptotic death (apoptotic index = 23.2%) in the former cases (Figure 5D and E). Immunohistochemical staining showed that STAT3, p-STAT3 and its downstream genes c-Myc, cyclinD1, survivin and VEGF could be detected in either cytoplasm or the nuclei of tumor tissues in NaCl control group but became apparently reduced in resveratrol-treated tumors (Figure 6; Table 2).
Short-term Resveratrol Treatment Promoted the Nuclear Translocation of Sirt1 and p53

Resveratrol is known as an activator of silent mating type information regulation 2 homolog (Sirt1) that modulates p53 activity by deacetylation [28,29]. Therefore, the in vitro and in vivo influences of resveratrol on Sirt1 activity of EJ cells were investigated by the methods of ICC, IHC and IF. As shown in Figure 7, both Sirt1 and p53 were distributed in cytosolic space of EJ cells and transplanted tumors without resveratrol treatment, which were apparently translocated into the nuclei of EJ cells after in vitro 2 h 200 μM Res treatment at 72 h time-point and 2 h intravesical resveratrol instillation for 13 times, suggesting potential functional link of these two proteins.

No Obvious Local Irritation of Resveratrol-treated Bladder Mucosa

Intravesical resveratrol instillation was conducted on both female tumor-free ICR mice and the female tumor-bearing nude mice. By the end of the experiment, the whole bladders were removed and fixed in 10% neutral buffered formalin for H/E staining-based cystitis examination. As shown in Figure 8A, the transitional epithelia of urinary bladder walls were intact, and
neither distinct capillary congestion nor inflammatory lymphocyte infiltration was observed in the sub-mucosal space of resveratrol-treated cancer-free ICR mice. Similar situation was also found in the tumor surrounding bladder tissues of tumor-bearing nude mice treated by intravesical resveratrol instillation (data not shown). In contrast, severe epithelial damage, capillary congestion and hemorrhage could be observed in the MMC-treated urinary bladders of ICR mice (Figure 8A). The distinct body weight loss was found in MMC-treated group (18.1 g in average) in comparison with that in Res-treated group (27.2 g in average; \( P < 0.01 \); Figure 8B and 8C).

Discussion

Transitional cell carcinoma of urinary bladder/TCC is responsible for over 130 000 annual deaths worldwide [30] largely due to the recurrence and metastasis [2]. Intravesical administration of anticancer agents has been adopted to eradicate residual tumor cells [3,4]. However, those conventional therapies can not last long because of systemic toxicity and local irritation [2]. Since resveratrol is non-toxic [5] and exerts inhibitory effects on TCC cells [9–12], it would be an alternative candidate for the management of TCCs if its anti-TCC capacity can be further proved under the experimental conditions closer to the clinical statuses. To mimic intravesical drug instillation, the cultured EJ TCC cells were treated with 100 \( \mu M \), 150 \( \mu M \) or 200 \( \mu M \) resveratrol transiently instead of constantly. The results clearly demonstrated that 150 \( \mu M \) and 200 \( \mu M \) resveratrol treatments for 1.5-hour or 2-hour were sufficient to suppress growth and induce apoptosis of EJ cells, suggesting that short-term resveratrol treatment could achieve similar anti-TCC effects as that of conventional drugs [14]. This notion was further supported by the downregulation of STAT3 and STAT3 target gene expression and reduction of p-STAT3 nuclear translocation in resveratrol-treated EJ cells, because activated STAT3 signaling was associated with TCC cell growth and survival [26]. These promising in vitro results encourage us to testify whether short-term resveratrol instillation can also lead to similar therapeutic consequence in an appropriate orthotopic xenograft model.

Although anti-cancer effects of resveratrol have been evidenced, this agent has not yet been applied to clinical practice largely due to the low intracellular bioavailability of systemically administrated resveratrol [31,32]. Unlike solid tumors in majority of organs, TCCs grow outward to the bladder cavity. Moreover, the instilled drug can be easily retained in the bladder and directly exerts its effects on the tumor tissue/cells. Therefore, an orthotopic xenograft model was established in nude mouse urinary bladder, which was then treated by resveratrol in the same dosages as that of the in vitro experiment and in the manner similar with clinical practice [14]. It was found that the tumor growth was remarkably suppressed and tumor cells underwent extensive apoptosis. Since the experiment was performed on the tumors inside the bladder, the results obtained were closer to the patients’ reality and, therefore, would be of translational values.

One of the severe side-effects of intravesical chemotherapy with conventional anticancer drugs is hemorrhagic cystitis [33]. Although the non-toxicity of resveratrol to normal cells has been described in some organs [32], the effect(s) of resveratrol on normal urinary bladder tissue remains unknown. Therefore, an effective anti-TCC dose of resveratrol (200 \( \mu M \)) was instilled into the bladders of cancer-free mice and compared with that treated by 2 mg/ml mitomycine C. Meanwhile, the response(s) of transplanted tumors and their surrounding mucosa to resveratrol were compared. We found that both the cancer-free and the tumor-surrounding mucosa showed almost intact transitional epithelia without distinct capillary congestion and inflammatory lymphocyte infiltration, while severe irritation and epithelial damage happened to the mitomycine C-treated mucosa. Our data thus provide in vivo evidence of cancer-targeting property of resveratrol in the urinary bladder and further suggest the suitability of resveratrol in clinical treatment of human TCCs.
Resveratrol possesses multifaceted molecular effects including inhibition of STAT3 signaling [20] and activation of Sirt1 deacetylation [28]. STAT3 activation is frequent in TCCs and its inhibition may lead to growth arrest and apoptosis [26]. We found that STAT3 signaling is also activated in EJ TCC cells and short term in vitro and in vivo resveratrol treatments can inhibit STAT3 activation and down-regulate the expression of STAT3 and its downstream cancer-associated genes. These results together with the similar findings from other types of cancers [20,32,34] suggest that STAT3 is a major molecular target of resveratrol. The suppressed growth of AG490-treated EJ cells further supports the critical roles of activated STAT3 signaling in promoting TCC cell proliferation. The lack of apoptotic death in AG490-treated EJ population indicates that resveratrol may alter other cell survival machineries beyond STAT3 signaling. So far, the role of Sirt1 in TCC formation and progression remains unclear. In this study, Sirt1 nuclear translocation is evidenced in resveratrol-treated EJ cells, paralleled with p53 nuclear translocation. It has been reported that Sirt1 nucleocytoplasmic shuttling plays a critical role in the regulation of Sirt1 activity [35]. Moreover, activated Sirt1-p53 pathway can induce senescence-like growth arrest of cancer cells [36]. Our results thus provide a cue to explore additional anti-TCC mechanism of resveratrol and to elucidate the biological implications of nuclear co-translocation of Sirt1 and p53 proteins.

In conclusions, the safety and efficacy of resveratrol in clinical treatment of bladder TCCs have been validated here by shortly exposing the cultured human TCC EJ cells and orthotopic transplanted tumors to resveratrol. Two hours 200 μM resveratrol treatment is sufficient to suppress in vitro and in vivo growth and to induce distinct apoptosis of EJ cells, presumably through inhibition of STAT3 activation and induction of Sirt1 and p53 nuclear translocation. Moreover, resveratrol neither exerts harmful effects on normal urothelial cells nor causes bladder hemorrhagic cystitis and body weight loss. Our results obtained from the clinically relevant experimental models strongly suggest the practical values of resveratrol in the management of human TCCs.

Acknowledgments

We thank Xue Gao for her skilful preparation of paraffin-embedded tissue blocks for this study.

Author Contributions

Conceived and designed the experiments: MLW HL JL. Performed the experiments: MLW LJY XYC QYK XS XHS. Analyzed the data: MLW HL LJY. Contributed reagents/materials/analysis tools: JL. Wrote the paper: MLW HL JL. Obtained permission for use of cell line: JL.

References

1. Cheung G, Sahai A, Billia M, Daogupta P, Khan MS (2013) Recent advances in the diagnosis and treatment of bladder cancer. BMC Med 11: 13.
2. Houghton BB, Chalasani V, Hayne D, Grimison P, Brown CS, et al. (2013) Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int 111: 977–983.
3. Passe-Leite R, Araujo-Rodrigues R, Palmeira G, Colaco R, Lopes C, et al. (2015) Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer. Biomed Pharmacother 67: 116–121.
4. Barlow LJ, Benson MC (2013) Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer. Curr Urol Rep 14: 65-70.
5. Chien HJ, Hsu LS, Shia YT, Lin MW, Lin CM (2012) The β-catenin/TCF complex as a novel target of resveratrol in the Wnt/β-catenin signaling pathway. Biochem Pharmacol 84: 1143–1153.
6. Yasen A, Chen S, Hock S, Rosato R, Dent P, et al. (2012) Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. Mol Pharmacol 82: 1030–1041.
7. Leon-Galicia I, Diaz-Chavez G, Garcia-Villa E, Uribe-Figueroa L, Hidalgo M, Vazquez A, et al. (2013) Resveratrol induces downregulation of DNA repair genes in MCF-7 human breast cancer cells. Eur J Cancer Prev 22: 11–20.
8. Wen S, Li H, Wu ML, Fan SH, Wang Q, et al. (2011) Inhibition of NF-kB signaling commits resveratrol-treated medulloblastoma cells to apoptosis without neuronal differentiation. J Neuro-oncol 104: 169–177.
9. Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, et al. (2010) Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 101: 408–493.
10. Lin X, Wu G, Hao WQ, Zhang Y, Jin FS (2012) Resveratrol induces apoptosis associated with mitochondrial dysfunction in bladder carcinoma cells. Int J Urol 19: 757–764.
11. Stocco B, Toledo K, Salvador M, Paulo M, Koyama N, et al. (2012) Dose-dependent effect of resveratrol on bladder cancer cells: chemoprevention and oxidative stress. Maturitas 72: 78–86.
12. Garcia Mediero JM, Ferruelo Alonso A, Paiz Borda A, Lujan Galan M, Angulo A, et al. (2013) Resveratrol induces down-regulation of DNA repair genes in MCF-7 human breast cancer cells. Eur J Cancer Prev 22: 11–20.
13. Parada LF, Tabin CJ, Shih C, Weinberg RA (1982). Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297: 474–478.
14. Liu J, Wang Q, Wang X, Sun Y, Chen XY, et al. (2003) Apoptosis of bladder cancer cells induced by short-term and low-dose Misonidazole-C: potential molecular mechanism and clinical implication. Int J Mol Med 11: 389–394.
15. Colombo R, Rocchini I, Suardi N, Benigni F, Colizzi G, et al. (2012) Nonsignificant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 62: 797–802.
16. Gibb CP, Kukaczek VG, Reith JD, Tchiginaova O, Sudov ON, et al. (2005) Stem-like cells in bone sarcomas: implications for tumorgenesis. Neoplasia 7: 967–976.
17. Beguchi M, Kaibara N (2001) Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer. Int J Mol Med 6: 661–666.
18. Grotzer MA, Hogarty MD, Jans AJ, Liu X, Zhao H, et al. (2001) MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7: 2425–2433.
19. Simale MM, De Miglio-MR, Moroni MR, Frau M, Asara JG, et al. (2004) Down-regulation of c-myc and Cyclin D1 genes by antineurclide deoxyribonucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. CancerGenes 25: 333–341.
20. Yu LJ, Wu ML, Li H, Chen NY, Wang Q, et al. (2008) Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells. Neoplasia 10: 736–744.
21. Cirione M, Di Renzo L, Lotti LV, Conte V, Trivedi P, et al. (2012) Primary effusion lymphoma cell death induced by bortezomib and AG490 activates dendritic cells through CD91. PLoS ONE 7: e31732.
22. Chan E, Patel A, Heston W, Larchian W (2009) Mouse orthotopic models for bladder cancer research. BJU Int 104: 1296–1291.
23. Vachon P, Faubert S, Blais D, Comito J, Bienvenu JG (2000) A pathophysiological study of abdominal organs following intraperitoneal injections of chloral hydrate in rats: comparison between two anesthesia protocols. Lab Anim 34: 84–90.
24. Chen C, Zhou H, Liu X, Liu Z, Ma Q (2011) Reduced Expression of von Hippel-Lindau Protein Correlates with Decreased Apoptosis and High Chondrosarcoma Grade. J Bone Joint Surg Am 93: 1833-1840.
25. Haaslachka BA, Adomat H, Fazli L, Fraedt Y, Andersen RJ, et al. (2008) Intravesical chemotherapy of high-grade bladder cancer with HT1-296, a synthetic analogue of the marine sponge product hemiasterlin. Clin Cancer Res 14: 1510–1518.
26. Chen CL, Chen L, Kohout J, Hutzler B, Chan C, et al. (2008) Signal transducer and activator of transcription 5 activation is associated with bladder cancer cell growth and survival. Mol Cancer 7: 78.
27. Chan ES, Patel AR, Hansel DE, Larchian WA, Heston WD (2012) Sunitinib malate provides activity against murine bladder tumor growth and invasion in an orthotopic tumor model. Urology 80: e17–e21.
28. Zou T, Yang Y, Xia F, Huang A, Gao X, et al. (2013) Resveratrol Inhibits CD14+ T cell activation by enhancing the expression and activity of Sirt1. PLoS ONE 8: e75193.
29. Hori YS, Kurokawa J, Uozumi M, Takahashi K, Takeyama H, et al. (2013) Resveratrol protects liver cancer cells from the chemotherapeutic agent doxorubicin. J Hepatol 58: 599–606.
30. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of the global cancer burden: 2008. Lancet Oncol 11: 49-57.
32. Shu XH, Li H, Sun XX, Wang Q, Sun Z, et al. (2011) Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. PLoS ONE 6: e27484.

33. Abraham P, Isaac B, Ramamoorthy H, Natarajan K (2011) Oral glutamine attenuates cyclophosphamide-induced oxidative stress in the bladder but does not prevent hemorrhagic cystitis in rats. J Med Toxicol 27: 118–124.

34. Quoc Trung L, Espinoza JL, Takami A, Nakao S (2013) Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS ONE 8: e55183.

35. Tong C, Morrison A, Mattison S, Qian S, Bryniarski M, et al. (2013) Impaired SIRT1 nucleocytoplasmic shuttling in the senescent heart during ischemic stress. FASEB J 27: 4332–4342.

36. Takwi A, Li Y (2009) The p53 pathway encounters the microRNA world. Curr Genomics 10: 194–197.